Cyclana Bio

Cyclana Bio is a biotechnology company developing human tissue-based models to investigate endometriosis and identify therapeutic targets.

Its research combines endometrial tissue biopsies and menstrual fluid samples with molecular profiling and three-dimensional disease models, focusing on extracellular matrix changes and inflammatory mechanisms.

Its 500-participant PEMP observational study began recruitment in 2026 through NHS hospitals. The resulting biological data are intended to improve disease stratification and support drug discovery for women's health conditions.